A shikonin derivative, β-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases

Anti-Cancer Drugs

Volumn 14, Issue 9, 2003, Pages 683-693

  Nakaya, Kazuyasu ^a   Miyasaka, Tadashi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Cancer; Inhibitor of tyrosine kinase; Protein tyrosine kinase; Shikonin; hydroxyisovalerylshikonin

Indexed keywords

(3 HYDROXYISOVALERYL)SHIKONIN; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; AG 537; BCR ABL PROTEIN; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBSTATIN; ERLOTINIB; GEFITINIB; GENISTEIN; IMATINIB; LAPATINIB; PD 0165557; PD 146568; PD 173074; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SHIKONIN DERIVATIVE; TX 1123; TX 1233; UNCLASSIFIED DRUG; VATALANIB;

APOPTOSIS; COMPETITIVE INHIBITION; DRUG BINDING SITE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0242319847     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200310000-00002     Document Type: Review

References (78)

1. Hunter T. Protein kinases and phosphatases: the Yin and Yang of protein phosphorylation and signaling. Cell 1995; 80:225-236.
2. Al-Obeidi FA, Lam KS. Development of inhibitors for protein tyrosine kinases. Oncogene 2000; 19:5690-5701.
3. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997; 1333:F217-F248.
4. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3-7.
5. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Role as anticancer agents. Drugs 2000; 59:753-767.
6. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267:1782-1788.
7. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharamacol Ther 2002; 93:79-98.
8. Druker BJ, Tamura S, Buchunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl-positive cells. Nat Med 1996; 2:561-566.
9. McWhirter JR, Galasso DL, Wang JYJ. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993; 13:7587-7595.
10. Lugo TG, Pendergast A-M, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-1082.
11. bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-830.
12. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990; 87:6649-66153.
13. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45:321-334.
14. s induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-β-D- arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ 1996; 7:1617-1623.
15. Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins CL, Green DR, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 1998; 91:1700-1705.
16. O'Dwyer ME, Druker BJ. Chronic myelogenous leukemia - new therapeutic principles. J Intern Med 2001; 250:3-9.
17. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-145.
18. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-932.
19. Sjoblom T, Shimizu A, OBrien KP, Pietras K, Cin PD, Buchdunger E, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61:578-5783.
20. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CDM, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20:5054-5058.
21. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
22. Couzin J. Smart weapons prove tough to design. Science 2002; 298:522-525.
23. Hashimoto S, Xu M, Masuda Y, Aiuchi T, Nakajo S, Cao J, et al. β-Hydroxyisovaleryl-shikonin inhibits cell giowth of various cancer cell lines and induces apoptosis in leukemia HL-60 cells by a mechanism different from those of Fas and etoposide. J Biochem 1999; 125:17-23.
24. Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y, Otsuka H, Shibata S, et al. Antitumor activity of shikonin and its derivatives. Chem Pharm Bull 1977; 25:2392-2395.
25. Hashimoto S, Xu Y, Masuda Y, Aiuchi T, Nakajo S, Uehara Y, et al. β-Hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res 2002; 93:944-951.
26. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, et al. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot (Tokyo) 1986; 39:170-173.
27. Hori T, Kondo T, Tsuji T, Imoto M, Umezswa K. Inhibition of tyrosine kinase and src oncogene functions by stable eibstatin analogues. J Antibiot (Tokyo) 1992; 45:280-282.
28. Onoda T, Inuma H, Sasaki Y, Hamada W, Isshiki K, Naganawa H, et al. Isolation of a novel tyrosine kinase inhibitor, lavendastin-A from Streptomyces griseolavendus. J Nat Prod 1989; 52:1252-1257.
29. Umezawa K, Imoto M. Use of erbstatin as protein-tyrosine kinase inhibitor. Methods Enzymol 1991; 201:379-385.
30. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGR-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242:933-935.
31. Hori H, Nagasawa H, Ishibashi M, Uto Y, Hirata A, Saijo K, et al. TX-1123: an antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity. Bioorg Med Chem 2002; 10:3257-3265.
32. Burger AM, Kaur G, Alley MC, Supko JG, Malspeis L, Grever MR, et al. Tyrphostin AG17, [(3,5-di-tert-butyl-4-hydroxybenzylidene)-malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res 1995; 55:2794-2799.
33. Gazit A, Osherov N, Gilon C, Levitzki A. Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrphostins: potent inhibitors of EGF receptor tyrosine kinase in vitro. J Med Chem 1996; 39:4905-4911.
34. Ick1. J Med Chem 1993; 36:425-432.
35. Graziani Y, Erikson E, Erikson RL. The effects of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur J Biochem 1983; 135:583-589.
36. Gschwendt M, Horn F, Kittstein W, Marks F. Inhibition of the calcium-and phospholipid-dependent protein kinase activity from mouse brain cytosol by quercetin. Biochem Biophys Res Commun 1983; 117:444-447.
37. Matter WF, Brown RF, Vlahos CJ. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun 1992; 186:624-631.
38. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262:5592-5595.
39. Bridges AJ. The rationale and strategy used to develop a series of highly potent, irreversible inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999; 6:825-843.
40. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al. Discovery of a novel, potent, and Src family-selective kinase inhibitor. J Biol Chem 1996; 271:695-701.
41. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60:2926-2935.
42. Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, et al. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 2001; 7:2563-2572.
43. Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, et al. Use of a pharmacophore model for the design of EGFR-tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997; 40:3601-3616.
44. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HDH, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 1996; 39:267-276.
45. Rewcastle GW, Murray DK, Elliot WL, Fry DW, Howard CT, Nelson JM, et al. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)- pyrido[3,4-d]pyrimidine (PD1 58780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J Med Chem 1998; 41:742-751.
46. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect of potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
47. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-4848.
48. Xia W, Mullin RJ, Keith BR, Liu L-H, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibtor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21:6255-6263.
49. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94.
50. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang X-Y, James CD, et al. The Her tyrosine kinase inhibitor Cl1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001; 61:739-748.
51. Mohammadi M, Froum S, Hamby JH, Schroeder MC, Panek RL, Lu GH, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17:5896-5904.
52. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 1999; 59:6145-6152.
53. Kraker AJ, Hartl BG, Amar AM, Barvian MR, Schwalter HDH, Moore CW. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d] pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 2000; 60:885-898.
54. Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000; 60:3127-3131.
55. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60:4152-4160.
56. Showalter HDH, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, et al. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N-and 3-substituted 2,2′-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners. J Med Chem 1997; 40:413-426.
57. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59:99-106.
58. Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun Li, et al. Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells. Cancer Res 2001; 61:3660-3668.
59. Bold G, Altman K-H, Frei J, Lang M, Manley PW, Traxler P, et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 2000; 43:2310-2323.
60. Lin B, Podar K, Gupta D, Tai Y-T, Li S, Weller E, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK767/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002; 62:5019-5026.
61. Uehara Y, Murakami Y, Suzukake-Tsuchiya K, Moriya Y, Sano H, Shibata K, et al. Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity. J Antibiot (Tokyo) 1988; 41:831-834.
62. Cassinelli G, Lanzi C, Pensa T, Gambetta RA, Nasini G, Cuccuru G, et al. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin. Biochem Pharmcol 2000; 59:1539-1547.
63. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997; 385:595-602.
64. Sicher F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997; 385:602-609.
65. Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 1994; 45:673-683.
66. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62:4236-4243.
67. Ward WHJ, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994; 48:659-666.
68. c-src tyrosine kinase, Part 1: hydroxynaphthalene derivatives. Bioorg Med Chem Lett 2000; 10:477-481.
69. Zheng Z-B, Nagai S, Imanami N, Kobayashi A, Natori S, Sankawa U. Inhibition effects of 5-S-glutathionyl-N-β-alanyl-L-dopa analogues against Src protein tyrosine kinase. Chem Pharm Bull 1999; 47:777-782.
70. Xu Y, Kajimoto S, Nakajo S, Nakajo S, Nakaya K. β- Hydroxyisovalerylshikonin and cisplatin act synergistically to inhibit growth and to induce apoptosis of human lung cancer DMS114 cells via a tyrosine kinase-dependent pathway. Oncology 2003; in press.
71. Masuda Y, Nishida A, Hori K, Hirabayashi T, Kajimoto S, Nakajo S, et al. β-Hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibition the activity of a polo-like kinase 1. Oncogene 2003; 22:1012-1023.
72. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-880.
73. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002; 21:8804-8816.
74. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 2000; 96:3195-3199.
75. 3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 2001; 15:772-778.
76. Kelly LM, Yu J-C, Boulton CL, Apatira M, Li J, Sullivan CM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1:421-432.
77. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1:433-443.
78. Hunter T. 1001 protein kinases redux - towards 2000. Semin Cell Biol 1994; 6:367-376.